Morning After Pill – Politics Slaps Science Down, And Wins

Even though America has, by far, the highest rates of unwanted and unplanned teenage pregnancies in the developed world, and the FDA wanted to make the Morning-After-Pill, otherwise known as Plan B One-Step, available as an over-the-counter (OTC) drug to all females of reproductive age, HHS Secretary Kathleen Sebelius slapped them down and said “No”…

Bisphosphonates – New Labeling Data On Long-term Usage Recommended By FDA Advisory Panel

Bisphosphonates, medications for the treatment and prevention of osteoporosis and other bone conditions, should have additional data on their labels on treatment duration, an FDA Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee (the Panel) recommended. However, the panel did not go as far as advising that specific time limits be included…

FDA Warns Against Placing A Mesh Through The Vagina To Repair Pelvic Organ Prolapse

The surgical placement of mesh via the vagina to repair pelvic organ prolapse may be riskier for the patient compared to other surgical procedures, the FDA (Food and Drug Administration) has warned doctors. The FDA adds that other options carry less risk than this transvaginal surgical procedure…

Dr. Pinkerton on Menopause and health management

In the last part of my interview, Dr. JoAnn V. Pinkerton discusses menopause and healthcare management for healthier postmenopausal years! (PRISTIQ for hot flash treatment pending FDA approval)

Columbia Laboratories' NDA For PROCHIEVE® Vaginal Progesterone Gel Accepted For Filing By FDA

Columbia Laboratories, Inc. (Nasdaq: CBRX) and Watson Pharmaceuticals, Inc. (NYSE: WPI) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Columbia’s New Drug Application (NDA) for PROCHIEVE® (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy…

« Previous Page — Next Page »